Daily treatment with Bylvay (odevixibat) safely and effectively eases itching and lowers blood bile acid levels, a sign of liver damage, in children and adolescents…
News
HEPATITIS
NewsHepatitis Awareness Month promotes screening, vaccination
Throughout May, the U.S. Centers for Disease Control and Prevention (CDC) will work with public health partners to raise awareness of viral hepatitis…
CHOLANGITIS
NewsNew molecule to reduce liver scarring a potential PSC treatment
Researchers at the University of California San Diego (UCSD) have created a molecule, named antisense oligonucleotide (ASO) 56, that is able to potently reduce liver…
CHOLESTASIS
NewsLow-dose soybean emulsion may avoid newborn cholestasis: Study
A reduced dose of soybean fat emulsion seems to be better than the standard dose at preventing parenteral nutrition-associated cholestasis in newborns undergoing surgery…
FATTY LIVER DISEASE
NewsUS government to launch 1st study of disease prevalence in MASLD
The U.S. government soon will launch a first national study to assess the prevalence of metabolic dysfunction-associated steatotic liver disease, or MASLD — a liver…
BILIARY ATRESIA
NewsTriple blood test may be best at diagnosing biliary atresia
The blood levels of two proteins, called MMP-7 and SOX9, are significantly higher in infants with biliary atresia than in those with similar liver…
Gilead Sciences has awarded $4 million in funding via its ALL4LIVER grant program to organizations worldwide whose community-based efforts will help the World Health…
CHOLANGITIS
NewsUDCA plus elafibranor best for treatment-resistant PBC: Analysis
Combining ursodeoxycholic acid (UDCA) with elafibranor, an experimental oral therapy for primary biliary cholangitis (PBC), may be the best treatment combination for lessening signs…
CHOLESTASIS
NewsType of intrahepatic cholestasis shows abnormal cellular processes
The levels of more than 250 proteins are abnormal in lab-grown liver organoids, or mini-livers, derived from a mouse model of progressive familial intrahepatic…
FATTY LIVER DISEASE
NewsFXR314 well tolerated, lowers liver fat, Phase 2 MASH trial shows
FXR314, an investigational oral therapy, safely and effectively reduced liver fat content in adults with a severe form of fatty liver disease called metabolic…
Recent Posts
- Experimental ICP drug volixibat shows early promise for mothers, babies
- Celebrating a major milestone with a 5th birthday party for the ages
- In proof-of-concept trial, daily pill lowers blood, liver fat levels in MASLD
- Rare biliary atresia variant linked to better clinical outcomes: China study
- New test detects hepatitis B in 1 hour with a finger prick: Study